Peptide Therapy · Investigational · Real RCT evidence
Kisspeptin for Sexual Health
& Hormonal Optimization
Kisspeptin sits at the top of the hormonal cascade that drives sexual desire and testosterone production. It’s also one of the more rigorously studied peptides on this site — real randomized, placebo-controlled trials exist, from one of the world’s leading reproductive endocrinology research groups. The results are genuinely interesting, and genuinely mixed.
Overview
What kisspeptin actually is
Kisspeptin is a naturally occurring neuropeptide (the product of the KISS1 gene) that acts as a master regulator of the reproductive system. It sits at the very top of the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal signaling chain that controls the release of GnRH, which in turn triggers LH and FSH release from the pituitary, which then drives testosterone production in the testes.
Because of this position at the top of the cascade, kisspeptin is being researched both for its direct effects on sexual arousal and desire (independent of hormone levels) and for its potential role in treating reproductive hormone disorders more broadly.
The strongest human data on kisspeptin and sexual health comes from a research group at Imperial College London (led by Prof. Waljit Dhillo), who have published a series of randomized, placebo-controlled trials in both men and women with hypoactive sexual desire disorder (HSDD) — a much higher standard of evidence than most peptides discussed for sexual health.
What the actual RCT found
A 2023 randomized trial in men with HSDD — the honest results
Published in JAMA Network Open, this randomized, placebo-controlled crossover trial studied 32 men with hypoactive sexual desire disorder. The results genuinely diverge depending on how you measure “worked” — which is worth understanding clearly rather than picking only the flattering half.
Objective measures — brain activity and physiological response
Kisspeptin significantly modulated brain activity in key sexual-processing brain regions compared to placebo, and increased sexual behavior and penile tumescence in response to visual sexual stimuli during the trial.
Self-reported arousal and desire scores
Despite the brain-activity and physiological changes, kisspeptin did not significantly alter participants’ own questionnaire-based ratings of sexual arousal and desire (measured via the Sexual Arousal and Desire Inventory) compared to placebo.
In plain terms: kisspeptin clearly activated the upstream hormonal signal (LH and FSH) and produced measurable physiological and brain-imaging changes — but this single acute-dose trial did not show a corresponding rise in testosterone, nor a change in how aroused participants said they felt. The researchers describe this as “early promise,” not proof of a working treatment.
A practical note
How the trial administered it vs. how it’s marketed off-label
The Imperial College trial administered kisspeptin via a monitored intravenous infusion (1 nmol/kg/hour for 75 minutes) in a clinical research setting — quite different from the subcutaneous injection protocols commonly sold off-label through compounding sources. The IV-infusion research protocol and any off-label injectable product are not necessarily equivalent in dosing, absorption, or effect, and no peptide-based kisspeptin product is FDA-approved for any indication.
Common questions
Frequently asked questions
Does kisspeptin raise testosterone?
Not directly, based on the best available trial data. A 2023 randomized trial found kisspeptin significantly raised LH and FSH — the pituitary signals that normally drive testosterone production — but did not produce a measurable increase in testosterone itself during the single-dose study. Its role in longer-term testosterone optimization protocols remains an open research question, not an established outcome.
Does kisspeptin actually increase arousal and desire?
The evidence is genuinely mixed. In the same 2023 trial, kisspeptin increased brain activity in sexual-processing regions and physiological arousal (penile tumescence) in response to visual stimuli — but did not significantly change participants’ own questionnaire-based ratings of how aroused or desirous they felt. Objective and subjective measures didn’t move together in this trial.
Is kisspeptin FDA-approved?
No. Kisspeptin remains investigational for any indication — sexual health, hormonal optimization, or otherwise. The research described on this page comes from controlled academic clinical trials, not from an approved commercial product.
Related
Other peptides to consider
Considering kisspeptin?
Given how early-stage and mixed this evidence is, a detailed conversation with a specialist is essential. Search our directory or ask in the forum first.
Key source: Mills, Ertl, Wall, et al., “Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial,” JAMA Network Open (2023)
This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Kisspeptin is investigational and not FDA-approved for any indication. Always consult a licensed physician before pursuing any treatment. PhallusMD does not endorse specific providers or compounding sources.
There are no reviews yet. Be the first one to write one.